Two-Year Treatment of Growth Hormone (GH) Receptor Deficiency with Recombinant Insulin-Like Growth Factor I in 22 Children: Comparison of Two Dosage Levels and to GH-Treated GH Deficiency

1997 ◽  
Vol 82 (2) ◽  
pp. 629-633 ◽  
Author(s):  
J. Guevara-Aguirre
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Gh Deficiency ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Gh Receptor ◽  
Recombinant Insulin ◽  
Growth Factor I

Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women

2009 ◽  
Vol 10 (12) ◽  
pp. 1844-1852 ◽  
Author(s):  
Laura J. Ghiron ◽  
Janice L. Thompson ◽  
Leah Holloway ◽  
Raymond L. Hintz ◽  
Gail E. Butterfield ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Bone Turnover ◽  
Elderly Women ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Recombinant Insulin ◽  
Growth Factor I

Plasma free insulin-like growth factor I concentrations in growth hormone deficiency in children and adolescents

1996 ◽  
Vol 134 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Yukihiro Hasegawa ◽  
Tomonobu Hasegawa ◽  
Makoto Takada ◽  
Yutaka Tsuchiya
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Gh Deficiency ◽  
Hormone Deficiency ◽  
Insulin Like Growth Factor ◽  
Igf Binding Proteins ◽  
Factor I ◽  
Igf I ◽  
Igf Binding ◽  
Growth Factor I

Hasegawa Y, Hasegawa T, Takada M, Tsuchiya Y. Plasma free insulin-like growth factor I concentrations in growth hormone deficiency in children and adolescents. Eur J Endocrinol 1996;134:184–9. ISSN 0804–4643. Serum levels of total insulin-like growth factor I (IGF-I) correlate with growth hormone (GH) secretory status and are a useful parameter in the diagnostic evaluation of GH deficiency. Serum total IGF-I levels represent the combined quantity of free or unbound IGF-I and IGF-I that is bound to specific IGF binding proteins. Free IGF-I (fIGF-I), which is postulated to be the bioactive fraction, accounts for only a small fraction of the total amount. We have recently developed a new immunoradiometric assay (IRMA) for plasma fIGF-I and have investigated fIGF-I in relation to GH status. The simple, non-extraction assay procedure involves the capture of unbound IGF-I by anti-IGF-I antibody coated to polystyrene beads and detection by a radiolabelled anti-IGF-I antibody directed to a separate epitope. Preliminary studies demonstrated that the f IGF-I IRMA does not measure IGF-I that is complexed to IGF-binding proteins and that the equilibrium between the free and bound fractions is not disturbed during the assay. Free IGF-I levels were compared to total IGF-I levels measured in the same IRMA after acid–ethanol extraction of the samples. Normal levels of fIGF-I from infancy through adulthood were found to have a close correlation with total IGF-I levels, with the lowest levels occurring in infancy and peak levels during puberty. Patients with complete GH deficiency had low levels of both fIGF-I and total IGF-I, with 94% and 100% of the levels below the 5th percentile for age, respectively. On the other hand, approximately 90% of patients with normal IGF binding protein-3 levels among partial GH deficiency and normal short children had free and total IGF-I levels above the 5th percentile for age. These data indicate that the clinical utility of plasma fIGF-I measurements is similar to measurements of total IGF-I in the evaluation of childhood GH deficiency. Yukihiro Hasegawa, Division of Endocrinology and Metabolism, Tokyo Metropolitan Kiyose Children's Hospital, 1-3-1 Urnezono Kiyose, Tokyo 204, Japan

Sign in / Sign up

Export Citation Format

Share Document